Vericel Corporation
VCEL$2.10B
Mid CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaBURLINGTON357 employees
Drugs in Pipeline
3
Phase 3 Programs
3
Upcoming Catalysts
2
Next Catalyst
Jul 30, 2026
5wMarket Overview
Stock performance and key metrics
VCEL News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
MACI
Chondral Defect
autologous cultured chondrocytes on porcine collagen membrane
Articular Cartilage Defect
ixmyelocel-T
Ischemic Dilated Cardiomyopathy (IDCM)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
MACI | Phase 3 | Chondral Defect | - | - |
autologous cultured chondrocytes on porcine collagen membrane | Phase 3 | Articular Cartilage Defect | - | - |
ixmyelocel-T | Phase 3 | Ischemic Dilated Cardiomyopathy (IDCM) | - | - |
Chondral Defect
1 drug in this indication
Articular Cartilage Defect
1 drug in this indication
Ischemic Dilated Cardiomyopathy (IDCM)
1 drug in this indication
Peripheral Arterial Disease
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply